Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,375
Out of 4,829 analysts
9
Total ratings
11.11%
Success rate
-45.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.63 | +1,433.74% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $1.85 | +440.54% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $1.38 | +479.71% | 1 | Mar 11, 2024 | |
| CARM Carisma Therapeutics | Initiates: Overweight | $10 | $0.19 | +5,149.34% | 1 | Oct 3, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $28.40 | +195.77% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $6.45 | +520.16% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $5.95 | +84.87% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $4.34 | +383.87% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $3.62 | +24,761.88% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.63
Upside: +1,433.74%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $1.85
Upside: +440.54%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $1.38
Upside: +479.71%
Carisma Therapeutics
Oct 3, 2023
Initiates: Overweight
Price Target: $10
Current: $0.19
Upside: +5,149.34%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $28.40
Upside: +195.77%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $6.45
Upside: +520.16%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $5.95
Upside: +84.87%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $4.34
Upside: +383.87%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $3.62
Upside: +24,761.88%